10-Q: Scientific Industries Reports Narrowed Losses in Q3 2024 Amidst Cost-Cutting Measures

Scientific Industries saw a significant reduction in its loss from continuing operations in the third quarter of 2024, driven by cost reductions and increased revenue in both operating segments.

Summary

• Scientific Industries reported a loss from continuing operations of $1.18 million for the three months ended September 30, 2024, a significant improvement compared to the $2.20 million loss in the same period of 2023.
• The company's revenue increased by 7.1% to $2.77 million in Q3 2024, up from $2.59 million in Q3 2023, with growth in both the Benchtop Laboratory Equipment and Bioprocessing Systems segments.
• For the nine months ended September 30, 2024, the loss from continuing operations was $4.52 million, compared to a loss of $6.76 million for the same period in 2023.
• The company's revenue for the first nine months of 2024 was $7.90 million, a decrease of 5.7% compared to $8.37 million in the same period of 2023.
• The company's gross profit margin increased to 49.2% in Q3 2024 from 45.7% in Q3 2023, primarily due to higher margins in the Bioprocessing Systems segment.
• Operating expenses decreased significantly, particularly in selling expenses, due to strategic cost reductions.
• The company's cash flow from operations was negative $3.30 million for the nine months ended September 30, 2024, and the company has an accumulated deficit of $32.00 million.
• Management has expressed concerns about the company's ability to continue as a going concern without additional capital resources.

Sentiment

Score: 4

Explanation: The document shows some positive signs of improvement in cost management and gross profit, but the negative cash flow, accumulated deficit, and going concern warning significantly outweigh these positives. The company's financial position is precarious, and its future is uncertain without additional capital.

Positives

• The company significantly reduced its losses from continuing operations in Q3 2024 compared to Q3 2023.
• Revenue increased in both operating segments, indicating positive market response to the company's products.
• The gross profit margin improved, suggesting better cost management and pricing strategies.
• Operating expenses, particularly selling and R&D, were significantly reduced due to strategic cost-cutting measures.
• The company successfully raised capital through the issuance of common stock and warrants.
• The company implemented a voluntary Salary/Compensation Waiver Program to reduce operating costs and conserve cash.

Negatives

• The company experienced negative cash flows from operations of $3.30 million for the nine months ended September 30, 2024.
• The company has an accumulated deficit of $32.00 million as of September 30, 2024.
• Management has expressed substantial doubt about the company's ability to continue as a going concern without additional capital resources.
• Revenue for the first nine months of 2024 decreased by 5.7% compared to the same period in 2023.
• The Benchtop Laboratory Equipment segment saw a decrease in revenue, primarily due to reduced sales in China and lower sales of VIVID pill counters.
• The company maintains a full valuation allowance of $11.03 million against its consolidated net deferred tax asset.

Risks

• The company's ability to continue as a going concern is uncertain without securing additional capital resources.
• The company faces challenges in generating sufficient cash flow from operations to fund its short and long-term requirements.
• The company's reliance on the Benchtop Laboratory Equipment Operations for cash flow makes it vulnerable to market fluctuations in that segment.
• The company's accumulated deficit and negative cash flows raise concerns about its long-term financial stability.
• The company's dependence on external financing exposes it to risks associated with market conditions and investor sentiment.
• The company's business is subject to various risks, including product demand, market acceptance, competition, and adverse economic conditions.

Future Outlook

The company's management is making plans to secure additional capital resources, which may include capital from management and significant shareholders, as well as third-party equity and/or debt financing. However, there are no assurances that the company will be successful in accomplishing any of its plans.

Management Comments

• The company's loss from continuing operations decreased primarily due to decreased expenses resulting from operating cost reductions and increased net revenue.
• The increase in revenue from the Benchtop Laboratory Equipment Operations was driven by increased sales of Genie brand products in the U.S., and to a lesser extent increased sales of the Torbal divisions VIVID pill counter.
• The pharmacy industry is recovering from cash flow constraints caused by new regulations related to pharmacy direct and indirect renumeration fees DIR fees.
• The increase in gross profit is due primarily to higher gross margin percentage in the Bioprocessing Systems Operations, in part attributable to increased sales of the recently launched Multiparameter Sensor.
• Selling expenses decreased primarily due to the reduction of sales and marketing employees in conjunction to the strategic operational plan for the Bioprocessing Systems Operations.
• Research and development expenses decreased primarily due to the completion of new product developments in the current year and reduction of research and development expenditures in both operating segments.
• The company believes that its operating cash flows, cash and investment securities on hand, and the availability of its line of credit, are not sufficient to fund its cash requirements for the next 12 months.

Industry Context

The company operates in the laboratory equipment and bioprocessing sectors, which are influenced by research funding, pharmaceutical industry trends, and regulatory changes. The company's performance is affected by market demand for its products, competition, and economic conditions. The company's bioprocessing segment is benefiting from increased demand for its new sensor products, while the benchtop equipment segment is facing challenges due to market softness in China and regulatory changes in the pharmacy industry.

Comparison to Industry Standards

• Scientific Industries' performance is mixed when compared to industry standards.
• While the company has shown improvement in reducing losses and increasing gross profit margins, its revenue growth is lagging behind some competitors in the laboratory equipment and bioprocessing sectors.
• Companies like Thermo Fisher Scientific and Danaher Corporation, which are major players in the life sciences and diagnostics industries, have reported more robust revenue growth and profitability.
• In the bioprocessing sector, companies like Sartorius and Repligen have also shown stronger growth, driven by demand for biopharmaceutical manufacturing solutions.
• Scientific Industries' challenges in the benchtop equipment segment, particularly in China, highlight the competitive pressures in that market.
• The company's financial position, with negative cash flows and an accumulated deficit, is weaker than many of its larger competitors, raising concerns about its long-term sustainability.
• The company's reliance on external financing and its going concern warning are also significant deviations from industry norms for established companies.

Management Changes

Related Party Transactions

• The company paid $24,000 and $71,300, respectively, and $0 and $0, respectively, to Mr. John Nicols, a Director of the Company, for consulting services to the Bioprocessing Systems Operations segment during the three and nine months ended September 30, 2024 and 2023, respectively.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern warning.
• Employees may be affected by potential cost-cutting measures and the uncertainty surrounding the company's future.
• Customers may experience disruptions in product availability and support if the company's financial situation worsens.
• Suppliers and creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company needs to secure additional capital resources to continue as a going concern.
• Management is planning to obtain capital from management, significant shareholders, and third-party equity and/or debt financing.
• The company will continue to implement its strategic operational plan to reduce costs and improve efficiency.
• The company will focus on increasing market penetration of its new products, particularly the DOTS Multiparameter sensor.

Key Dates

Keywords

laboratory equipment, bioprocessing systems, financial results, cost reduction, revenue growth, operating expenses, cash flow, going concern, stock options, warrants, pharmacy, sensors